Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.

Porto I, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, Ten Berg J, Widimský P, Le Gall N, Zagar AJ, LeNarz LA, Miller D, Montalescot G; ACCOAST Investigators.

JACC Cardiovasc Interv. 2016 May 9;9(9):897-907. doi: 10.1016/j.jcin.2016.01.041.

2.

Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study.

Dudek D, Dziewierz A, Widimsky P, Bolognese L, Goldstein P, Hamm C, Tanguay JF, LeNarz L, Miller DL, Brown E, Ten Berg J, Montalescot G; ACCOAST Investigators.

Am Heart J. 2015 Nov;170(5):1025-1032.e2. doi: 10.1016/j.ahj.2015.07.017. Epub 2015 Jul 26.

PMID:
26542513
3.

Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.

Widimsky P, Motovska Z, Bolognese L, Dudek D, Hamm C, Tanguay JF, Ten Berg J, Brown E, LeNarz L, Miller DL, Montalescot G; ACCOAST Investigators.

Heart. 2015 Aug;101(15):1219-24. doi: 10.1136/heartjnl-2015-307686. Epub 2015 Jun 9.

PMID:
26060122
4.

Reply: Not All NSTEMIs Are Created Equal.

Montalescot G, Collet JP, Ecollan P, Bolognese L, Ten Berg J, Dudek D, Hamm C, Widimsky P, Tanguay JF, Goldstein P, Brown E, Miller DL, LeNarz L, Vicaut E; ACCOAST Investigators.

J Am Coll Cardiol. 2015 Apr 28;65(16):1718-1719. doi: 10.1016/j.jacc.2015.01.054. No abstract available.

5.

Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.

Montalescot G, Collet JP, Ecollan P, Bolognese L, Ten Berg J, Dudek D, Hamm C, Widimsky P, Tanguay JF, Goldstein P, Brown E, Miller DL, LeNarz L, Vicaut E; ACCOAST Investigators.

J Am Coll Cardiol. 2014 Dec 23;64(24):2563-2571. doi: 10.1016/j.jacc.2014.08.053.

6.

Factors associated with statin selection among privately insured commercial and Medicare patients.

Zhao Z, Bae J, Sponseller CA, Zhu Y, Kryzhanovski VA, LeNarz LA.

Curr Med Res Opin. 2013 Apr;29(4):395-404. doi: 10.1185/03007995.2013.776525. Epub 2013 Feb 27.

PMID:
23406054
7.

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.

Goodnough LT, Smith PK, Levy JH, Poston RS, Short MA, Weerakkody GJ, LeNarz LA.

J Thorac Cardiovasc Surg. 2013 Apr;145(4):1077-1082.e4. doi: 10.1016/j.jtcvs.2012.07.059. Epub 2012 Sep 17.

8.

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ, Lenarz LA.

J Am Coll Cardiol. 2012 Jul 31;60(5):388-96. doi: 10.1016/j.jacc.2012.03.030. Epub 2012 May 23.

9.

Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Zhu B, Zhao Z, McCollam P, Anderson J, Bae JP, Fu H, Zettler M, Lenarz L.

Curr Med Res Opin. 2011 Mar;27(3):633-41. doi: 10.1185/03007995.2010.551657. Epub 2011 Jan 18.

PMID:
21241206
10.

Resource utilization and healthcare costs for acute coronary syndrome patients with and without diabetes mellitus.

Zhao Z, Zhu B, Anderson J, Fu H, LeNarz L.

J Med Econ. 2010;13(4):748-59. doi: 10.3111/13696998.2010.535661. Epub 2010 Nov 24.

PMID:
21091396
11.

Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.

Daemen J, Simoons ML, Wijns W, Bagust A, Bos G, Bowen JM, Braunwald E, Camenzind E, Chevaliers B, DiMario C, Fajadeto J, Gitt A, Guagliumi G, Hillege HL, James S, Jüni P, Kastrati A, Kloth S, Kristensen SD, Krucoff M, Legrand V, Pfisterer M, Rothman M, Serruys PW, Silber S, Steg PG, Tariah I, Wallentin L, Windecker SW, Aimonetti A, Allocco D, Berenger M, Boam A, Calle JP, Campo G, Carlier S, de Schepper J, Di Bisceglie G, Dobbels H, Farb A, Ghislain JC, Hellbardt S, ten Hoedt R, Isaia C, de Jong P, Lekehal M, LeNarz L, Mhullain FN, Nagai H, Patteet A, Paunovic D, Potgieter A, Purdy I, Raveau-Landon C, Ternstrom S, Van Wuytswinkel J, Waliszewski M; European Society of Cardiology.

EuroIntervention. 2009 Jan;4(4):427-36. No abstract available.

12.

ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.

Daemen J, Simoons ML, Wijns W, Bagust A, Bos G, Bowen JM, Braunwald E, Camenzind E, Chevalier B, Dimario C, Fajadet J, Gitt A, Guagliumi G, Hillege HL, James S, Jüni P, Kastrati A, Kloth S, Kristensen SD, Krucoff M, Legrand V, Pfisterer M, Rothman M, Serruys PW, Silber S, Steg PG, Tariah I, Wallentin L, Windecker SW, Aimonetti A, Allocco D, Baczynska A, Bagust A, Berenger M, Bos G, Boam A, Bowen JM, Braunwald E, Calle JP, Camenzind E, Campo G, Carlier S, Chevalier B, Daemen J, de Schepper J, Di Bisceglie G, Dimario C, Dobbels H, Fajadet J, Farb A, Ghislain JC, Gitt A, Guagliumi G, Hellbardt S, Hillege HL, Ten Hoedt R, Isaia C, James S, de Jong P, Jüni P, Kastrati A, Klasen E, Kloth S, Kristensen SD, Krucoff M, Legrand V, Lekehal M, Lenarz L, Ni Mhullain F, Nagai H, Patteet A, Paunovic D, Pfisterer M, Potgieter A, Purdy I, Raveau-Landon C, Rothman M, Serruys PW, Silber S, Simoons ML, Steg PG, Tariah I, Ternstrom S, Van Wuytswinkel J, Waliszewski M, Wallentin L, Wijns W, Windecker SW.

Eur Heart J. 2009 Jan;30(2):152-61. doi: 10.1093/eurheartj/ehn510. Epub 2008 Nov 26. No abstract available.

13.

Clinical and economic outcomes of medication therapy management services: the Minnesota experience.

Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, Brown LM, Cipolle RJ.

J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):203-11; 3 p following 211. doi: 10.1331/JAPhA.2008.07108.

PMID:
18359733
14.

Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.

Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ENDEAVOR III Investigators.

J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7. Epub 2006 Nov 28.

15.

Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals.

Isetts BJ, Brown LM, Schondelmeyer SW, Lenarz LA.

Arch Intern Med. 2003 Aug 11-25;163(15):1813-20.

16.

Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.

Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, Sapp SK, Cabot CF, Tcheng JE, Califf RM, Effron MB, Topol EJ.

Ann Thorac Surg. 2000 Aug;70(2):516-26.

PMID:
10969673
17.

Coronary artery bypass graft in abciximab-treated patients.

LeNarz LA.

Ann Thorac Surg. 2000 Aug;70(2 Suppl):S38-42.

PMID:
10966009
18.

Management of esophageal gunshot wounds.

Pass LJ, LeNarz LA, Schreiber JT, Estrera AS.

Ann Thorac Surg. 1987 Sep;44(3):253-6.

PMID:
3632110
19.

Improved graft patency associated with altered platelet function induced by marine fatty acids in dogs.

Casali RE, Hale JA, LeNarz L, Faas F, Morris MD.

J Surg Res. 1986 Jan;40(1):6-12.

PMID:
3001406
20.

The sore psoas: a difficult diagnosis in childhood.

Smith S, Lenarz L, Mollitt DL, Golladay ES.

J Pediatr Surg. 1982 Dec;17(6):975-8.

PMID:
7161686

Supplemental Content

Loading ...
Support Center